The invention claimed is:

1. A compound selected from:

(3 S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate mesylate having a melting point of 189° C., and

(3 S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate sulfate $1.5H_2O$ having a melting point of 106° C.

2. A pharmaceutical composition comprising:

the compound according to claim **1**, and

one or more suitable excipients.

3. The compound according to claim **1**, which is (3 S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate mesylate having a melting point of 189° C.

4. The compound according to claim **3** having a purity of greater than 99.5%.

5. The compound according to claim **3** having an enantiomeric purity of greater than 99.5%.

6. The compound according to claim **1**, which is (3 S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate sulfate $1.5H_2O$ having a melting point of 106° C.

7. The compound according to claim **6** having a purity of greater than 99.3%.

8. The compound according to claim **6** having an enantiomeric purity of greater than 99.3%.